Clinicopathological factors associated with the amplification of the HER2 /neu gene in patients with breast cancer HER2 2+

Authors

  • Rosa América Meléndez Guevara Médico especialista en Anatomía Patológica. Jefa del Servicio de Patología Quirúrgica y Necropsias del Hospital Nacional Guillermo Almenara.
  • Angélica Yeyli Asencio Aguedo Médico especialista en Anatomía Patológica, Médico Asistente del Servicio de Patología Quirúrgica y Necropsias del Hospital Nacional Guillermo Almenara.

DOI:

https://doi.org/10.15381/anales.v78i4.14257

Keywords:

HER2, in situ hybridization (ISH), Breast cancer.

Abstract

Introduction: A subgroup of breast carcinomas overexpress epidermal growth factor-2 (HER2). The determination of this overexpression is carried out by immunohistochemistry. The difficulty of diagnosis by this method arises when the result is ambiguous (2+), thus it is necessary to perform in situ hybridization (ISH) to determine the amplification of the HER2/neu gene. Objective: To determine if, in HER2 2+ cases, the amplification of the HER 2 / neu gene is associated with prognostic clinicopathological factors. Design: Observational, cross-sectional, descriptive study. Institution: Surgical pathology service, Guillermo Almenara Irigoyen Hospital. Lima, Peru. Participants: Cases of breast cancer HER2 2+. Methodology: We studied 117 cases of Her2 2+ breast cancer diagnosed between the years 2010 - 2015, to which ISH was subsequently performed. All the data were analyzed with the statistical program SPSS 22. The Chi-square test was used to analyze the association between the variables. Main results measures: Factors associated with the amplification of the HER2 / neu gene. Results: Amplification of the HER2 / neu gene was observed in 41% of the total cases. In these, a histological grade III (66%), lymph node involvement (61%), tumor size ≥ 2 cm (86%) and Ki 67 ≥ 20% (83%) were observed more frequently. A statistically significant association was found with an age ≥ 50 years (X2 test, P = 0,004) and histological grade III (X2 test, P = 0.017). Conclusion: Amplification of the HER2/ neu gene in ambiguous cases is associated with an age ≥50 years and histological grade III

Downloads

Published

2018-03-23

Issue

Vol. 78 No. 4 (2017)

Section

Artículo Original

License

Copyright (c) 2018 Anales de la Facultad de Medicina

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Those authors who have publications with this magazine accept the following terms:

  1. Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
  2. Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
  3. Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).

How to Cite

1.
Meléndez Guevara RA, Asencio Aguedo AY. Clinicopathological factors associated with the amplification of the HER2 /neu gene in patients with breast cancer HER2 2+. An Fac med [Internet]. 2018 Mar. 23 [cited 2024 Jul. 17];78(4):381-5. Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/14257